Blood concentrations and pharmacodynamic effects of betaxolol (SL 75212) a new beta‐adrenoceptor antagonist after oral and intravenous administration.
Open Access
- 1 November 1980
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 10 (5) , 449-452
- https://doi.org/10.1111/j.1365-2125.1980.tb01787.x
Abstract
1 In normal subjects, intravenous betaxolol given in doses which inhibited the tachycardia of exercise failed to affect the peak expiratory flow rate. 2 From 2 to 48 h after administration of 150 micrograms/kg in four normal subjects, there was no significant difference between the blood levels, whether given orally or intravenously. 3 At all times, heart rate and blood pressure, at rest and during exercise, were reduced equally after administration by both routes, but the area under the curve of exercise heart rate against time was significantly smaller (P < 0.05) after intravenous drug. 4 The absolute bioavailability of betaxolol was 89 +/‐ 5%.Keywords
This publication has 6 references indexed in Scilit:
- Medi-cal: a debacle?1980
- Blood concentrations and pharmacodynamic effects of SL 75212, a new beta-adrenoceptor antagonist, after oral and intravenous administration [proceedings]Published by Wiley ,1979
- The spectrofluorimetric estimation and buccal absorption of SL 75212, a novel beta-adrenoceptor antagonist [proceedings]Published by Wiley ,1979
- Sensitive gas chromatographic method for the determination in blood and urine of SL 75212 [4-(2-cycloporpylmethoxytheyl)-1-phenoxy-3-isopropyl- aminograpan-2-ol], a new β1 adrenoceptor blocking agentJournal of Chromatography A, 1979
- IGPHARM: Interactive graphic package for pharmacokinetic analysisComputers and Biomedical Research, 1978